Our results provide lines of evidence that the PSPC1/IGF1R axis is the critical signaling to facilitate cancer cell motility and potentially as a therapeutic biomarker to predict malignant subtypes of cancer for receiving treatments with IGF1R inhibitor. The gene discussed is PSPC1; the disease is cancer.